

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 15, 2023

Enovix Corporation

(Exact Name of Registrant as Specified in Its Charter)

Delaware

(State or Other Jurisdiction  
of Incorporation)

001-39753

(Commission  
File Number)

85-3174357

(IRS Employer  
Identification No.)

3501 W. Warren Avenue  
Fremont, California

(Address of Principal Executive Offices)

94538

(Zip Code)

Registrant's Telephone Number, Including Area Code: (510) 695-2350

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value \$0.0001 per share	ENVX	The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

#### Item 5.07 Submission of Matters to a Vote of Security Holders.

On June 15, 2023, Enovix Corporation (the “**Company**”) held its 2023 Annual Meeting of Stockholders (the “**Annual Meeting**”). At the Annual Meeting, the Company’s stockholders voted on four proposals, each of which is described in more detail in the Company’s definitive proxy statement filed with the U.S. Securities and Exchange Commission (the “**SEC**”) on April 28, 2023, as supplemented by a proxy statement supplement filed with the SEC on June 13, 2023 (the “**Proxy Statement**”). The following is a brief description of each matter voted on at the Annual Meeting, including the number of votes cast with respect to each matter and, if applicable, the number of abstentions and broker non-votes with respect to each matter.

##### Proposal 1 – Election of Directors

Stockholders approved the election of each of the Company’s six (6) directors to serve for a one-year term until the Company’s 2024 Annual Meeting of Stockholders. The results of the voting were as follows:

<b>Nominee</b>	<b>Voting Result</b>	<b>For</b>	<b>Withheld</b>	<b>Broker Non-Votes</b>
Thurman J. “T.J.” Rodgers	Approved	59,627,686	3,297,563	40,333,596
Betsy Atkins	Approved	50,873,521	12,051,728	40,333,596
Pegah Ebrahimi	Approved	50,693,285	12,231,964	40,333,596
Emmanuel T. Hernandez	Approved	62,070,232	855,017	40,333,596
Gregory Reichow	Approved	61,705,200	1,220,049	40,333,596
Dr. Raj Talluri	Approved	62,246,710	678,539	40,333,596

##### Proposal 2 – Compensation of Our Named Executive Officers

Stockholders approved, on an advisory basis, the compensation of the Company’s named executive officers as disclosed in the Proxy Statement. The results of the voting were as follows:

<b>Voting Result</b>	<b>For</b>	<b>Against</b>	<b>Abstain</b>	<b>Broker Non-Votes</b>
Approved	57,996,678	4,642,442	286,129	40,333,596

##### Proposal 3 – Frequency of Future Stockholder Advisory Votes on the Compensation of Our Named Executive Officers

Stockholders approved, on an advisory basis, holding future stockholder advisory votes on the compensation of the Company’s named executive officers every “one year.” The results of the voting were as follows:

<b>One Year</b>	<b>Two Years</b>	<b>Three Years</b>	<b>Abstain</b>	<b>Broker Non-Votes</b>
61,994,726	226,110	504,147	200,266	40,333,596

##### Proposal 4 – Ratification of Appointment of Independent Registered Accounting Firm for Fiscal Year 2023

Stockholders approved the ratification of the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023. The results of the voting were as follows:

<b>Voting Result</b>	<b>For</b>	<b>Against</b>	<b>Abstain</b>
Approved	102,741,074	204,604	313,167

---

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**Enovix Corporation**

Date: June 20, 2023

By: /s/ Steffen Pietzke

---

Steffen Pietzke  
Chief Financial Officer